Subcutaneous immunoglobulin 16.5 % given by the rapid push method in patients with inborn errors of immunity: a prospective multicenter study of quality of life

BACKGROUND: Replacement therapy with immunoglobulin preparations is the basic therapy for patients with impaired antibody formation in the context of inborn errors of immunity. The introduction of replacement therapy with subcutaneous immunoglobulin (SCIG) into clinical immunological practice has allowed patients with inborn errors of immunity, regardless of age, to carry out therapy independently at home. This circumstance has played a leading role in improving the quality of life of patients. AIM: To assess the quality of life of patients and adherence to therapy during the transition from intravenous immunoglobulin replacement therapy to SCIG therapy. MATERIALS AND METHODS: A total of 233 patients of different ages with inborn errors of immunity were enrolled in the study. All patients were switched from intravenous immunoglobulin to SCIG 16.5 % therapy. SCIG was administered every 7–10 days for at least 12 months via the rapid push method. Assessment of quality of life and adherence to SCIG therapy was carried out 6 and 12 months after the start of therapy using a questionnaire. RESULTS: Based on the results of the assessment of the quality of life of patients using a questionnaire, patients of all age groups under 18 years and their parents demonstrated improvement in the social sphere, academic performance at school, and physical activity against the background of switching to SCIG. According to the survey, 84 % of patients did not experience technical difficulties and 83 % wanted to continue the SCIG infusion. CONCLUSION: Performing manual infusion of SCIG at home has a positive effect on the quality of life of patients and helps improve adherence to therapy.